- Thinly traded nano cap Onconova Therapeutics (ONTX +17.7%) is up on a 5x surge in volume on the heels of a bullish call from H.C. Wainwright (BUY/$6) citing positive expectations from a Phase 3 clinical trial assessing lead candidate rigosertib in higher-risk myelodysplastic syndrome (MDS) patients. Topline data should be available by late H1 2018.
- Rigosertib is a small molecule that inhibits cellular signaling by acting as a Ras protein mimetic. Ras is a family of proteins that are involved in transmitting signals within cells. When switched "on", it activates other proteins that ultimately turn on genes involved in cell growth, differentiation and survival.
- On Wednesday, October 11, the company will host a Key Opinion Leader meeting focused on the diagnosis and treatment of RASopathies.
- Previously: Onconova completes end-of-Phase 2 meeting with FDA regarding lead product candidate rigosertib; informs on Phase 3 design (Sept. 26, 2016)
- Now read: Onconova Therapeutics (ONTX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
Original article